All lobbying filings

VIATRIS INC.

Lobbying for VIATRIS INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Pennsylvania · House · Senate · $590,000.00 expenses · posted Apr 21, 2025

Official filing document

Bills named in this filing 9

S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 891
Bipartisan Health Care Act
HR 9747
Continuing Appropriations and Extensions Act, 2025
S 775
Increasing Transparency in Generic Drug Applications Act
HR 1503
Prescription Information Modernization Act of 2023
S 2916
Prescription Information Modernization Act of 2023
S 2129
Ensuring Access to Lower-Cost Medicines for Seniors Act
HR 5461
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023

Lobbying activity 6

Health Issues

Part D Formulary Design and Generic Drug Tiering S. 1302 - Increasing Transparency in Generic Drug Applications Act H.R. 1843 - Increasing Transparency in Generic Drug Applications Act S. 775 - Increasing Transparency in Generic Drug Applications Act HR1503/S. 2916, Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act H.R. 5461 Ensuring Access to Lower-Cost Medicies for Seniors Act Drug Shortages S. 891, the Bipartisan Health Care Act

IP Issues related to generic medicines Patent Settlements S 2220, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S4638 2025 National Defense Authorization Act

Budget/Appropriations

HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.